06:52 Mon 24 Feb 2020
BkofA Merrill Lynch - Form 38.5 (b) - Allergan
FORM 38.5(b)
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997,
TAKEOVER RULES, 2013
DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITHOUT
RECOGNISED INTERMEDIARY STATUS, OR WITH RECOGNIZED INTERMEDIARY
STATUS BUT NOT DEALING IN A CLIENT-SERVING CAPACITY
1. |
KEY INFORMATION |
|
|
|
|
|
|
|
Common - IE00BY9D5467 |
|
|
|
2. |
INTERESTS AND |
(a) |
Interests and short positions (following dealing) in the class of relevant security |
Class of relevant security: Common |
IE00BY9D5467 |
|||||
|
Long |
Short |
||||
Number |
% |
Number |
% |
|||
|
2,022,350 |
0.615% |
1,427,395 |
0.434 % |
||
|
1,855,293 |
0.564% |
2,180,293 |
0.663% |
||
|
75,000 |
0.023% |
0 |
0% |
||
Total |
3,952,643 |
1.201% |
3,607,688 |
1.097% |
(b) |
Interests and short positions in relevant securities of the company, other than the |
Class of relevant security: |
|
|||||
|
Long |
Short |
||||
Number |
% |
Number |
% |
|||
|
0 |
0% |
0 |
0% |
||
|
0 |
0% |
0 |
0% |
||
|
0 |
0% |
0 |
0% |
||
Total |
0 |
0% |
0 |
0% |
3. |
DEALINGS (Note 3) |
(a) |
Purchases and sales |
Purchase/sale |
Number of relevant securities |
Price per unit (Note 4) |
Purchase |
200 |
|
Purchase |
100 |
|
Purchase |
47 |
|
Purchase |
808 |
|
Purchase |
118 |
|
Purchase |
1 |
|
Purchase |
15 |
|
Purchase |
99 |
|
Purchase |
200 |
|
Purchase |
113 |
|
Purchase |
1,077 |
|
Purchase |
701 |
|
Purchase |
518 |
|
Purchase |
1,034 |
|
Purchase |
1,190 |
|
Purchase |
6,000 |
|
Purchase |
635 |
|
Purchase |
114 |
|
Purchase |
2 |
|
Purchase |
138 |
|
Purchase |
1 |
|
Purchase |
331 |
|
Purchase |
89 |
|
Purchase |
115 |
|
Purchase |
50 |
|
Purchase |
151 |
|
Purchase |
230 |
|
Purchase/sale |
Number of relevant securities |
Price per unit (Note 4) |
Sale |
232 |
|
Sale |
100 |
|
Sale |
116 |
|
Sale |
232 |
|
Sale |
231 |
|
Sale |
115 |
|
Sale |
500 |
|
Sale |
262 |
|
Sale |
200 |
|
Sale |
299 |
|
Sale |
346 |
|
Sale |
200 |
|
Sale |
100 |
|
Sale |
295 |
|
Sale |
2 |
|
Sale |
691 |
|
Sale |
2,016 |
|
Sale |
1,059 |
|
Sale |
393 |
|
Sale |
100 |
|
Sale |
500 |
|
Sale |
300 |
|
Sale |
49 |
|
Sale |
600 |
|
Sale |
295 |
|
Sale |
500 |
|
Sale |
900 |
|
Sale |
115 |
|
Sale |
995 |
|
Sale |
314 |
|
Sale |
1,955 |
|
Sale |
369 |
|
Sale |
500 |
|
Sale |
100 |
|
Sale |
231 |
|
Sale |
100 |
|
Sale |
23 |
|
Sale |
293 |
|
Sale |
1,577 |
|
Sale |
1,053 |
|
Sale |
170 |
|
Sale |
659 |
|
Sale |
1 |
|
Sale |
200 |
|
Sale |
375 |
|
Sale |
13 |
|
Sale |
967 |
|
Sale |
1,431 |
|
Sale |
100 |
|
Sale |
6,176 |
|
Sale |
2,527 |
|
Sale |
15 |
|
Sale |
1,832 |
|
Sale |
4,522 |
|
Sale |
200 |
|
Sale |
1,843 |
|
Sale |
2,005 |
|
Sale |
300 |
|
Sale |
1,630 |
|
Sale |
708 |
|
Sale |
1,350 |
|
Sale |
492 |
|
Sale |
889 |
|
Sale |
506 |
|
Sale |
516 |
|
Sale |
230 |
|
Sale |
2,404 |
|
Sale |
300 |
|
Sale |
100 |
|
Sale |
15 |
|
Sale |
1,352 |
|
Sale |
2,076 |
|
Sale |
300 |
|
(b) |
Derivatives transactions (other than options transactions) |
Product name, |
Nature of transaction |
Number of relevant securities |
Price per unit |
Swaps |
Reducing a Short Position |
883 |
|
Swaps |
Opening a Short Position |
4,978 |
|
Swaps |
Opening a Short Position |
1,022 |
|
(c) |
Options transactions in respect of existing relevant securities |
(i) |
Writing, selling, purchasing or varying |
Product name, e.g. call option |
Writing, selling, purchasing, varying etc. |
Number of securities to which the option relates (Note 7) |
Exercise price |
Type, e.g. American, European etc |
Expiry date |
Option money paid/ received per unit (Note 4) |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
(ii) |
Exercising |
Product name, |
Number of securities |
Exercise price per |
N/A |
N/A |
N/A |
(d) |
Other dealings (including transactions in respect of new securities) (Note 3) |
Nature or transaction |
Details |
Price per unit |
|
|
|
Collateral Delivery |
Collateral Delivery of 16,200 shares |
N/A |
4. |
OTHER INFORMATION |
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person |
None |
Is a Supplemental Form 38.5(b) attached? (Note 8) |
Yes |
Date of disclosure |
|
Contact name |
Tolu Tade |
Telephone number |
+44207 996 3410 |
|
AbbVie Inc |
Nature of connection (Note 9) |
Advisor to - AbbVie Inc |
SUPPLEMENTAL FORM 38.5(b)
DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DETAILS OF OPEN POSITIONS
Product name, |
Written or |
Number of securities to which the option or derivative relates |
Exercise price |
Type, e.g. |
Expiry date |
Put Option |
Purchased |
75,000 |
|
American |
|
This information is provided by RNS, the news service of the
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE